In clinical trials of Pfizer Inc.'s (PFE) torcetrapib--a heart medication that is the most important drug in the company's pipeline--has been confirmed to raise blood pressure, according to this NYTimes.com article.
Pfizer, the world's largest drug company, will face serious setbacks if there are problems with this newest drug. Lipitor, the company's cholesterol-lowering drug, loses patent protection in 2010 and torcetrapib was the front runner to replace the $13 billion in annual sales that Lipitor currently generates for the company.
The company's stock dropped 2 percent after the announcement.
Comment Preview